Phase II trial of panitumumab, cisplatin and gemcitabine in bIliary tract cancer.

 

Trial Summary:

Phase II trial to evaluate the potential molecular profile of biliary tract cancer and the clinical benefit and safety of panitumumab, cisplatin and gemcitabine in the treatment of biliary tract cancer.

Supported By:

Cancer Australia; Amgen; NHMRC CTC; AGITG

Eligibility:

Patients with inoperable biliary tract cancer and a K-RAS wild-type oncogene status.

Registration ID:

ACTRN12611000245998

Participation:

Australia

Australian Lead Group:

AGITG

Status:

closed

Activation Date:

21/06/2012

Chairs:

Jenny Shannon 

Contact:

tactic@ctc.usyd.edu.au